Twist Bioscience and SOPHiA GENETICS Collaborate to Offer Optimized Genomic Solutions
Sequencing the whole genome is expensive and often does not provide the depth of information needed for individual genes and the role they play in complex diseases. Target enrichment enables genomic sequencing efforts to be focused in specific regions of interest, which reduces cost and analysis time. Genomic solutions that combine Twist NGS enrichment solutions along with the SOPHiA AI-powered Platform for advanced DNA analysis are designed to support the implementation of NGS application for somatic and germline testing.
“SOPHiA’s mission is to democratize access to Data-Driven Medicine all around the world. With the addition of SOPHiA’s technology to Twist’s advanced products, clinical researchers will benefit from end-to-end, highly-accurate and reliable genomic solutions,” commented Jurgi Camblong CEO and Co-founder of SOPHiA GENETICS. “The combined solution will ultimately help experts precisely detect and characterize genomic mutations and use that information to improve outcomes.”
“Genomics research is enabling a shift from broad-based “one-size-fits-all” approach to a personalized experience,” commented Emily M. Leproust, Ph.D., CEO and co-founder of Twist. “Pairing our industry-leading, rapidly customizable enrichment efficiency with SOPHiA’s robust analytical platform provides customers an important solution to achieve clinically actionable data while saving on sequencing costs. We are excited to work with SOPHiA to provide this new combined offering to clinical researchers around the world.”
About SOPHiA GENETICS
SOPHiA GENETICS is a health tech company democratizing Data-Driven Medicine to improve health outcomes and economics worldwide. By unlocking the power of new-generation health data for cancer and rare diseases management, the universal SOPHiA Platform allows clinical researchers to act with precision and confidence. The company’s innovative approach enables an ever-expanding community of over 1,000 institutions to benefit from knowledge sharing, fostering a new era in healthcare. SOPHiA’s achievement is recognized by the MIT Technology Review’s "50 Smartest Companies". More info: SOPHiAGENETICS.COM, follow @SOPHiAGENETICS on Twitter.
Legal Notice Regarding Forward-Looking Statements
This press release contains forward-looking statements. All statements other than statements of historical facts contained herein, including without limitation Twist’s reach to potential new customers as a result of the collaboration, and the ability for Twist’s products to help customers achieve clinically actionable data while saving costs, are forward-looking statements reflecting the current beliefs and expectations of management made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve known and unknown risks, uncertainties, and other important factors that may cause Twist Bioscience’s actual results, performance, or achievements to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others, the risks and uncertainties of the ability to attract new customers and retain and grow sales from existing customers; risks and uncertainties of rapidly changing technologies and extensive competition in synthetic biology could make the products